Disease activity of 38 patients with reactive arthritis treated with TNF inhibitors at baseline and the 6-month and 18-month visits, according to data from ICEBIO.
| Disease Activity | N* | Baseline | N | 6 Mos | N | 18 Mos | p |
|---|---|---|---|---|---|---|---|
| CRP | 31 | 26 (6; 42) | 23 | 6.0 (3.0; 7.0) | 22 | 5.6 (1.0; 4.5) | < 0.001 |
| SJC 28-joint | 32 | 2.8 (0; 3) | 23 | 1.3 (0.0; 0.0) | 22 | 0.5 (0.0; 0.0) | < 0.001 |
| TJC 28-joint | 32 | 3.8 (1.0; 4.3) | 23 | 0.7 (0.0; 1.0) | 22 | 0.9 (0.0; 0.8) | < 0.001 |
| VAS pain | 30 | 68 (55; 80) | 23 | 22 (5.0; 25) | 23 | 22 (6.5; 43) | < 0.001 |
| VAS fatigue | 28 | 57 (41; 77) | 23 | 25 (8.0; 29) | 23 | 29 (8.5; 54) | < 0.001 |
| DAS28-CRP | 30 | 4.1 (3.3; 4.9) | 22 | 2.2 (1.5; 3.0) | 22 | 2.2 (1.3; 2.5) | < 0.001 |
| CDAI | 23 | 20 (13; 24) | 16 | 4.7 (1.0; 6.5) | 20 | 4.5 (1.0; 6.0) | < 0.001 |
| HAQ | 29 | 0.99 (0.50; 1.50) | 24 | 0.31 (0.00; 0.41) | 23 | 0.35 (0.00; 0.69) | < 0.001 |
| Responders**, defined by: | |||||||
| VAS, SJC, TJC | 21 | 15 patients, 71% | 21 | 15 patients, 71% | |||
| DAS28-CRP | 20 | 18 patients, 90% | 20 | 17 patients, 85% |
↵* N denotes no. patients with data available for each variable. Data presented as means (25%; 75% quartiles).
↵** Responders defined as having a 30% or more reduction in VAS pain, SJC and TJC, or a DAS28-CRP score decrease by 1 or more disease activity categories. The Kruskal-Wallis test found a significant difference for all variables. CRP: C-reactive protein; DAS28-CRP: 28-joint count Disease Activity Score–CRP; CDAI: Clinical Disease Activity Index; HAQ: Health Assessment Questionnaire; SJC: swollen joint count; TJC: tender joint count; TNF: tumor necrosis factor; VAS: visual analog scale.